Korea Investment CORP Buys 8,500 Shares of Labcorp Holdings Inc. $LH

Korea Investment CORP raised its stake in Labcorp Holdings Inc. (NYSE:LH) by 36.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,858 shares of the medical research company’s stock after buying an additional 8,500 shares during the period. Korea Investment CORP’s holdings in Labcorp were worth $9,145,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Blair William & Co. IL increased its holdings in Labcorp by 190.8% in the 3rd quarter. Blair William & Co. IL now owns 11,697 shares of the medical research company’s stock worth $3,358,000 after purchasing an additional 7,675 shares in the last quarter. Baltimore Washington Financial Advisors Inc. grew its holdings in shares of Labcorp by 8.9% during the third quarter. Baltimore Washington Financial Advisors Inc. now owns 885 shares of the medical research company’s stock worth $254,000 after purchasing an additional 72 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Labcorp by 118.8% in the third quarter. First Trust Advisors LP now owns 188,236 shares of the medical research company’s stock valued at $54,035,000 after buying an additional 102,190 shares during the period. Foresight Global Investors Inc. bought a new position in Labcorp in the 3rd quarter valued at approximately $365,000. Finally, Skba Capital Management LLC boosted its position in Labcorp by 3.5% during the 3rd quarter. Skba Capital Management LLC now owns 2,960 shares of the medical research company’s stock worth $850,000 after buying an additional 100 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on LH. Robert W. Baird raised their price target on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. JPMorgan Chase & Co. upped their price target on Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Piper Sandler increased their price target on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Finally, Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $304.82.

Labcorp Stock Performance

LH stock opened at $270.27 on Thursday. The firm has a market cap of $22.27 billion, a PE ratio of 25.84, a price-to-earnings-growth ratio of 1.83 and a beta of 1.01. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The stock has a 50-day moving average price of $272.12 and a 200-day moving average price of $270.12. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72.

Labcorp (NYSE:LH) last released its earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. During the same quarter last year, the firm posted $3.45 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities research analysts expect that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Friday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s dividend payout ratio is currently 27.53%.

Insider Activity at Labcorp

In other news, CEO Adam H. Schechter sold 8,705 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the sale, the executive vice president owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. This represents a 17.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 16,113 shares of company stock valued at $4,547,450. 0.84% of the stock is currently owned by company insiders.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.